Monoclonal antibodies and cocktails for treatment of Ebola infections
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
1. A monoclonal antibody or an antigen binding fragment thereof comprising
a heavy chain CDR1 comprising SEQ ID NO: 41, a heavy chain CDR2 comprising SEQ ID NO: 42, a heavy chain CDR3 comprising an amino acid sequence with zero or one amino acid substitution relative to SEQ ID NO: 43, wherein the one amino acid substitution occurs at amino acid residue 100, 101, 102, 106, 107, 108, 109, 110, or 111 in the heavy chain, using SEQ ID NO: 15 as a reference; and
a light chain CDR1 comprising SEQ ID NO: 44, a light chain CDR2 comprising SEQ ID NO: 45, and a light chain CDR3 comprising SEQ ID NO: 46;
wherein the antigen to which the antigen binding fragment binds comprises Ebola glycoprotein, and wherein the one amino acid substitution, if present, is selected from the group consisting of H100A, R101A, V102A, G106A, Y107A, H108A, F109A, D110A, and Y111A.
2. The monoclonal antibody of claim 1 , wherein said monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 15; and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 18.
3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody or antigen binding fragment that binds to an Ebola glycoprotein antigen thereof comprises predominantly a single glycoform.
4. The monoclonal antibody of claim 3 , wherein the single glycoform is one of GnGn, G1/G2, and NaNa.
5. The monoclonal antibody of claim 3 , wherein the single glycoform substantially lacks at least one of fucose and xylose.
6. A composition for treating Ebola, wherein the composition comprises a therapeutically effective amount of a monoclonal antibody and a pharmaceutically acceptable excipient or carrier,
wherein the monoclonal antibody or an antigen binding fragment thereof comprises a heavy chain CDR1 comprising SEQ ID NO: 41, a heavy chain CDR2 comprising SEQ ID NO: 42, a heavy chain CDR3 comprising an amino acid sequence with zero or one amino acid substitution relative to SEQ ID NO: 43, wherein the one amino acid substitution occurs at amino acid residue 100, 101, 102, 106, 107, 108, 109, 110, or 111 in the heavy chain, using SEQ ID NO: 15 as a reference,
a light chain CDR1 comprising SEQ ID NO: 44, a light chain CDR2 comprising SEQ ID NO: 45, and a light chain CDR3 comprising SEQ ID NO: 46,
wherein the antigen to which the antigen binding fragment binds comprises Ebola glycoprotein, and wherein the one amino acid substitution, if present, is selected from the group consisting of H100A, R101A, V102A, G106A, Y107A, H108A, F109A, D110A, and Y111A.
7. The composition of claim 6 , wherein the composition further comprises a second monoclonal antibody or antigen binding fragment thereof, wherein said second monoclonal antibody or antigen binding fragment thereof binds Ebola glycoprotein.
8. The composition of claim 7 , wherein the second monoclonal antibody or antigen binding fragment thereof comprises a heavy chain CDR1 comprising SEQ ID NO: 53, a heavy chain CDR2 comprising SEQ ID NO: 54, a heavy chain CDR3 comprising SEQ ID NO: 55, and
a light chain CDR1 comprising SEQ ID NO: 56, a light chain CDR2 comprising SEQ ID NO: 57, and a light chain CDR3 comprising SEQ ID NO: 58, wherein the antigen to which the antigen binding fragment binds comprises an Ebola glycoprotein.
9. The composition of claim 7 , wherein said second antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 12; and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 14.
10. The composition of claim 7 further comprising a third monoclonal antibody or antigen binding fragment thereof, wherein said third monoclonal antibody or antigen binding fragment thereof binds an Ebola glycoprotein.
11. A method for treating Ebola infection in a patient, the method comprising administering to the patient a composition comprising a therapeutically effective amount of a first monoclonal antibody or an antigen binding fragment thereof,
wherein the monoclonal antibody or an antigen binding fragment thereof comprises a heavy chain CDR1 comprising SEQ ID NO: 41, a heavy chain CDR2 comprising SEQ ID NO: 42, a heavy chain CDR3 comprising an amino acid sequence with zero or one amino acid substitution relative to SEQ ID NO: 43, wherein the one amino acid substitution occurs at amino acid residue 100, 101, 102, 106, 107, 108, 109, 110, or 111 in the heavy chain, using SEQ ID NO: 15 as a reference, and
a light chain CDR1 comprising SEQ ID NO: 44, a light chain CDR2 comprising SEQ ID NO: 45, and a light chain CDR3 comprising SEQ ID NO: 46;
wherein the antigen to which the antigen binding fragment binds comprises Ebola glycoprotein, and wherein the one amino acid substitution, if present, is selected from the group consisting of H100A, R101A, V102A, G106A, Y107A, H108A, F109A, D110A, and Y111A.
12. The method of claim 11 , wherein said monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 15; and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 18.
13. The method of claim 11 , wherein the composition further comprises a second antibody, wherein the second antibody or antigen binding fragment thereof comprises a heavy chain CDR1 comprising SEQ ID NO: 53, a heavy chain CDR2 comprising SEQ ID NO: 54, a heavy chain CDR3 comprising SEQ ID NO: 55, and
a light chain CDR1 comprising SEQ ID NO: 56, a light chain CDR2 comprising SEQ ID NO: 57, and a light chain CDR3 comprising SEQ ID NO: 58, wherein the antigen to which the antigen binding fragment binds comprises an Ebola glycoprotein.
14. The method of claim 13 , wherein said second antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 12; and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 14.
15. The method of claim 13 , wherein said first and said second monoclonal antibodies or antigen binding fragments thereof each bind at least two species of Ebola glycoprotein.
16. The method of claim 13 , wherein the first and the second monoclonal antibodies or antigen binding fragments thereof that bind to an Ebola glycoprotein antigen comprise predominantly single glycoforms.
17. The method of claim 13 , wherein the predominantly single glycoforms are one of GnGn, G1/G2, and NaNa.
18. The method of claim 13 , wherein the predominantly single glycoforms substantially lack at least one of fucose and xylose.